Remove Events Remove Image Interpretation Remove Radiation Remove Radiation Oncology
article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

“PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. POSLUMA use contributes to a patient’s overall long-term cumulative radiation exposure.

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Of the identified lesions, 16-25 were successfully verified (predominantly using follow-up imaging as SoT) as TP, providing a M1 VDR of 8.1-13%, Gauden, D.Phil. 13%, across the 3 readers.